Advances in Cancer Research最新文献_第6页

Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy. 组织特异性和癌症选择性基因启动子在癌症诊断和治疗中的应用。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-04-20 DOI: 10.1016/bs.acr.2023.03.005

Amit Kumar, Swadesh K Das, Luni Emdad, Paul B Fisher

{"title":"Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy.","authors":"Amit Kumar, Swadesh K Das, Luni Emdad, Paul B Fisher","doi":"10.1016/bs.acr.2023.03.005","DOIUrl":"10.1016/bs.acr.2023.03.005","url":null,"abstract":"Current treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene therapy represents a targeted approach that in principle could significantly reduce undesirable side effects in normal tissues while significantly inhibiting tumor growth and progression. To be effective, this strategy requires a clear understanding of the molecular biology of cancer development and evolution and developing biological vectors that can serve as vehicles to target cancer cells. The advent and fine tuning of omics technologies that permit the collective and spatial recognition of genes (genomics), mRNAs (transcriptomics), proteins (proteomics), metabolites (metabolomics), epiomics (epigenomics, epitranscriptomics, and epiproteomics), and their interactomics in defined complex biological samples provide a roadmap for identifying crucial targets of relevance to the cancer paradigm. Combining these strategies with identified genetic elements that control target gene expression uncovers significant opportunities for developing guided gene-based therapeutics for cancer. The purpose of this review is to overview the current state and potential limitations in developing gene promoter-directed targeted expression of key genes and highlights their potential applications in cancer gene therapy.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"160 ","pages":"253-315"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10233094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance. Lnc-ing表观遗传机制与自噬和癌症耐药性。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-04-07 DOI: 10.1016/bs.acr.2023.03.002

Sandhik Nandi, Atanu Mondal, Aritra Ghosh, Shravanti Mukherjee, Chandrima Das

{"title":"Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance.","authors":"Sandhik Nandi, Atanu Mondal, Aritra Ghosh, Shravanti Mukherjee, Chandrima Das","doi":"10.1016/bs.acr.2023.03.002","DOIUrl":"10.1016/bs.acr.2023.03.002","url":null,"abstract":"Long noncoding RNAs (lncRNAs) comprise a diverse class of RNA molecules that regulate various physiological processes and have been reported to be involved in several human pathologies ranging from neurodegenerative disease to cancer. Therapeutic resistance is a major hurdle for cancer treatment. Over the past decade, several studies has emerged on the role of lncRNAs in cancer drug resistance and many trials have been conducted employing them. LncRNAs also regulate different cell death pathways thereby maintaining a fine balance of cell survival and death. Autophagy is a complex cell-killing mechanism that has both cytoprotective and cytotoxic roles. Similarly, autophagy can lead to the induction of both chemosensitization and chemoresistance in cancer cells upon therapeutic intervention. Recently the role of lncRNAs in the regulation of autophagy has also surfaced. Thus, lncRNAs can be used in cancer therapeutics to alleviate the challenges of chemoresistance by targeting the autophagosomal axis. In this chapter, we discuss about the role of lncRNAs in autophagy-mediated cancer drug resistance and its implication in targeted cancer therapy.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"160 ","pages":"133-203"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10241612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Racial disparities in pancreatic cancer clinical trials: Defining the problem and identifying solutions. 胰腺癌临床试验中的种族差异：界定问题并找出解决方案。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-03-13 DOI: 10.1016/bs.acr.2023.02.009

Allison N Martin, Rebecca A Snyder

引用次数: 1

Prediction and validation of molecular biological mechanism of Fuzheng Huayu capsule in the treatment of liver cancer 扶正化瘀胶囊治疗肝癌分子生物学机制的预测与验证

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.53388/2023623007

Zi-Ning Wang, Ayesha T Tahir, Sabahat Waris, Wenbo Cheng, Jun Kang

引用次数: 0

Commentary on "Rethinking the International Response System to Global Health Threats: Strengthening International Collaboration to Ensure Vaccine Equity and Combat Vaccination Hesitancy". 关于 "反思全球健康威胁的国际应对系统：加强国际合作，确保疫苗公平，消除疫苗接种犹豫 "的评论。

IF 1 2区医学

Advances in Cancer Research Pub Date : 2022-03-01 DOI: 10.14423/SMJ.0000000000001366

Steven T Baldwin

引用次数: 0

Development history of hysteromyoma surgery with uterus preservation and introduction to each operation 子宫肌瘤保留子宫手术的发展历史及每次手术的介绍

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522008

Wenqi Han

引用次数: 0

The perceptions and experiences of advanced cancer patients and their families in advance care planning: a systematic review and synthesis of qualitative studies 晚期癌症患者及其家属在预先护理计划中的看法和经验:定性研究的系统回顾和综合

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522025

Peng-Shuai Wu, Hong-Yang Liu, Meng-Ying Leng, Hai Zhao

引用次数: 0

Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. 针对临床流行病学背景的肝癌风险预测分子生物标志物。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2022-02-24 DOI: 10.1016/bs.acr.2022.01.005

Naoto Kubota, Naoto Fujiwara, Yujin Hoshida

{"title":"Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts.","authors":"Naoto Kubota, Naoto Fujiwara, Yujin Hoshida","doi":"10.1016/bs.acr.2022.01.005","DOIUrl":"10.1016/bs.acr.2022.01.005","url":null,"abstract":"Hepatocellular carcinoma (HCC) risk prediction is increasingly important because of the low annual HCC incidence in patients with the rapidly emerging non-alcoholic fatty liver disease or cured HCV infection. To date, numerous clinical HCC risk biomarkers and scores have been reported in literature. However, heterogeneity in clinico-epidemiological context, e.g., liver disease etiology, patient race/ethnicity, regional environmental exposure, and lifestyle-related factors, obscure their real clinical utility and applicability. Proper characterization of these factors will help refine HCC risk prediction according to certain clinical context/scenarios and contribute to improved early HCC detection. Molecular factors underlying the clinical heterogeneity encompass various features in host genetics, hepatic and systemic molecular dysregulations, and cross-organ interactions, which may serve as clinical-context-specific biomarkers and/or therapeutic targets. Toward the goal to enable individual-risk-based HCC screening by incorporating the HCC risk biomarkers/scores, their assessment in patient with well-defined clinical context/scenario is critical to gauge their real value and to maximize benefit of the tailored patient management for substantial improvement of the poor HCC prognosis.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"1-37"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10362331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel insights into molecular and immune subtypes of biliary tract cancers. 胆道癌症的分子和免疫亚型的新见解。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.01.008

Emily R Bramel, Daniela Sia

{"title":"Novel insights into molecular and immune subtypes of biliary tract cancers.","authors":"Emily R Bramel, Daniela Sia","doi":"10.1016/bs.acr.2022.01.008","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.01.008","url":null,"abstract":"Biliary tract cancers (BTCs), which include cholangiocarcinoma (CCA) and gallbladder cancer (GBC), are heterogenous malignancies characterized by distinct molecular features often associated with specific clinical traits and/or outcomes. Such complex molecular heterogeneity, both within each BTC subtype and between distinct subtypes, poses a great challenge to personalized medicine. Recent technological advances have allowed the integration of multiple -omics derived from large cohorts of patients with distinct solid cancers to ultimately design stratification algorithms for prognostic prediction or more efficient treatment allocation. In this regard, although BTCs lag behind other tumors when it comes to our understanding of their molecular complexity, over the past decade, tremendous efforts have been made to generate supervised or unsupervised molecular classifications. As a result, CCAs and GBCs can be assigned to distinct molecular and/or prognostic classes. Notably, the discovery of biologically relevant subgroups of tumors harboring frequent targetable alterations (i.e., mutations in IDH1, FGFR2 fusion proteins) holds important therapeutic implications for BTCs, particularly iCCA. Furthermore, the recent application of single cell-based technologies or more conservative (and less precise) \"virtual microdissection\" algorithms to isolate signals derived from the immune and stromal cells has identified the first microenvironment-based classes. In this chapter, we will review the molecular and immune classes of BTCs, with a particular focus on their clinical implications.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"167-199"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms and clinical significance of TGF-β in hepatocellular cancer progression. TGF-β在肝癌进展中的作用机制及临床意义。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.02.002

Sobia Zaidi, Nancy R Gough, Lopa Mishra

引用次数: 2